Will generic Wegovy be available in the UK soon?

So far, patents for semaglutide have expired or are expiring soon in countries like India, Canada, China, Turkey, South Africa, and Brazil.

Briefly, a medical patent gives a pharmaceutical company exclusive rights to make and sell a medicine for a set period of time. It’s basically like a ‘temporary monopoly’. So when a company like Novo Nordisk invests billions in developing a new drug, the government gives them that exclusivity to help them recoup their research costs.

But once the patent expires, other companies can make their own generic (usually cheaper) versions of the medication.

When this happens usually comes down to how different countries apply or interpret patent laws. As a rule of thumb, generics tend to appear earlier in countries like India or Brazil, where the legal threshold for extending a patent is often higher than in the UK.

What does this mean for the global weight loss injection market?

The semaglutide patent is set to expire in approximately 10 countries in 2026, and these countries together represent about 44% of the global population and around 48% of the global obesity burden. This is likely to have a massive impact, especially in terms of cost and accessibility.

Countries like India, where the patent expired in March 2026, have already seen around 40 pharmaceutical companies rushing in to develop new, lower-cost versions of semaglutide. In some estimates, prices could drop by as much as 80-90%, which means that weight loss treatments will become much more accessible.

The availability of generics could also really help ease global demand, as some regions, including the US and Europe, are still facing shortages and strong pressure on supply for weight-loss injections.

However, it’s important to remember that major markets like the UK, Europe, and the US still have active patents in place, and will do so until the early 2030s, so access to generics will be limited in these regions until then.

What does this mean for the weight loss injection market in the UK?

In the UK, the situation is quite different. The patent for semaglutide is expected to remain in place until around 2031. This means that generic versions of semaglutide cannot be legally produced or sold here until at least then.

A good comparison is Saxenda. Once its patent expired in the UK, generic versions like Nevolat and Plaobes became available through registered pharmacies.

You might be thinking, can’t we just import the cheap versions from India? This may seem tempting, but the reality is that even if other countries start producing semaglutide at much lower prices, those generics can’t be legally imported into the UK due to patent protection laws.

So for now, access remains limited to the original branded product.